메뉴 건너뛰기




Volumn 70, Issue 2, 2014, Pages 257-262.e3

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry

(370)  Piaserico, Stefano a   Cazzaniga, Simone b   Chimenti, S dn   Giannetti, A cl   MacCarone, Mara e   Picardo, Mauro f   Peserico, A a   Naldi, Luigi b   Griseta, V g   Miracapillo, A g   Azzini, M h   Mocci, L h   Michelini, M h   Offidani, A i   Bernardini, L i   Campanati, A i   Ricotti, G j   Giacchetti, A j   Norat, M k   Gualco, F k   more..


Author keywords

biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor alfa inhibitors

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

EID: 84892680565     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.10.019     Document Type: Article
Times cited : (58)

References (20)
  • 1
    • 47549107863 scopus 로고    scopus 로고
    • Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials
    • A.K. Brimhall, L.N. King, J.C. Licciardone, H. Jacobe, and A. Menter Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Br J Dermatol 159 2008 274 285
    • (2008) Br J Dermatol , vol.159 , pp. 274-285
    • Brimhall, A.K.1    King, L.N.2    Licciardone, J.C.3    Jacobe, H.4    Menter, A.5
  • 2
    • 84873427294 scopus 로고    scopus 로고
    • Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis
    • J. Leman, and A.D. Burden Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis Br J Dermatol 167 Suppl 2012 12 20
    • (2012) Br J Dermatol , vol.167 , pp. 12-20
    • Leman, J.1    Burden, A.D.2
  • 3
    • 84872852757 scopus 로고    scopus 로고
    • Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare registry
    • Psocare Study Group
    • P. Gisondi, S. Cazzaniga, S. Chimenti, A. Giannetti, M. Maccarone, M. Picardo Psocare Study Group Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare registry J Eur Acad Dermatol Venereol 27 2013 e30 e41
    • (2013) J Eur Acad Dermatol Venereol , vol.27
    • Gisondi, P.1    Cazzaniga, S.2    Chimenti, S.3    Giannetti, A.4    MacCarone, M.5    Picardo, M.6
  • 4
    • 84866401186 scopus 로고    scopus 로고
    • The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study
    • A.B. Gottlieb, R.E. Kalb, A. Blauvelt, M.P. Heffernan, H.L. Sofen, and L.K. Ferris et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study J Am Acad Dermatol 67 2012 642 650
    • (2012) J Am Acad Dermatol , vol.67 , pp. 642-650
    • Gottlieb, A.B.1    Kalb, R.E.2    Blauvelt, A.3    Heffernan, M.P.4    Sofen, H.L.5    Ferris, L.K.6
  • 5
    • 34447293977 scopus 로고    scopus 로고
    • Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics
    • M. Papoutsaki, M.S. Chimenti, A. Costanzo, M. Talamonti, A. Zangrilli, and A. Giunta et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics J Am Acad Dermatol 57 2007 269 275
    • (2007) J Am Acad Dermatol , vol.57 , pp. 269-275
    • Papoutsaki, M.1    Chimenti, M.S.2    Costanzo, A.3    Talamonti, M.4    Zangrilli, A.5    Giunta, A.6
  • 6
    • 70349323598 scopus 로고    scopus 로고
    • Experience with biologics for psoriasis in daily practice: Switching is worth a try
    • L.L. Lecluse, M. de Groot, J.D. Bos, and P.I. Spuls Experience with biologics for psoriasis in daily practice: switching is worth a try Br J Dermatol 161 2009 948 951
    • (2009) Br J Dermatol , vol.161 , pp. 948-951
    • Lecluse, L.L.1    De Groot, M.2    Bos, J.D.3    Spuls, P.I.4
  • 7
    • 68949148678 scopus 로고    scopus 로고
    • Efficacy and safety of etanercept in psoriasis after switching from other treatments: An observational study
    • A. Mazzotta, M. Esposito, A. Costanzo, and S. Chimenti Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study Am J Clin Dermatol 10 2009 319 324
    • (2009) Am J Clin Dermatol , vol.10 , pp. 319-324
    • Mazzotta, A.1    Esposito, M.2    Costanzo, A.3    Chimenti, S.4
  • 8
    • 79952812411 scopus 로고    scopus 로고
    • Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
    • B.E. Strober, Y. Poulin, F.A. Kerdel, R.G. Langley, Y. Gu, and S.R. Gupta et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study J Am Acad Dermatol 64 2011 671 681
    • (2011) J Am Acad Dermatol , vol.64 , pp. 671-681
    • Strober, B.E.1    Poulin, Y.2    Kerdel, F.A.3    Langley, R.G.4    Gu, Y.5    Gupta, S.R.6
  • 9
    • 43049086693 scopus 로고    scopus 로고
    • Efficacy of etanercept in psoriatic patients previously treated with infliximab
    • G. Pitarch, J.L. Sánchez-Carazo, L. Mahiques, and V. Oliver Efficacy of etanercept in psoriatic patients previously treated with infliximab Dermatology 216 2008 312 316
    • (2008) Dermatology , vol.216 , pp. 312-316
    • Pitarch, G.1    Sánchez-Carazo, J.L.2    Mahiques, L.3    Oliver, V.4
  • 10
    • 80052883932 scopus 로고    scopus 로고
    • An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab
    • R. Vender An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab J Drugs Dermatol 10 2011 396 402
    • (2011) J Drugs Dermatol , vol.10 , pp. 396-402
    • Vender, R.1
  • 11
    • 80051692385 scopus 로고    scopus 로고
    • Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumor necrosis factor agents: Subanalysis of BELIEVE
    • J.P. Ortonne, S. Chimenti, K. Reich, R. Gniadecki, P. Sprøgel, and K. Unnebrink et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumor necrosis factor agents: subanalysis of BELIEVE J Eur Acad Dermatol Venereol 25 2011 1012 1020
    • (2011) J Eur Acad Dermatol Venereol , vol.25 , pp. 1012-1020
    • Ortonne, J.P.1    Chimenti, S.2    Reich, K.3    Gniadecki, R.4    Sprøgel, P.5    Unnebrink, K.6
  • 12
    • 77957021921 scopus 로고    scopus 로고
    • Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: A retrospective case cohort study
    • R.T. Woolf, C.H. Smith, K. Robertson, and J.N. Barker Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study Br J Dermatol 163 2010 889 892
    • (2010) Br J Dermatol , vol.163 , pp. 889-892
    • Woolf, R.T.1    Smith, C.H.2    Robertson, K.3    Barker, J.N.4
  • 13
    • 77957021919 scopus 로고    scopus 로고
    • Switching from etanercept to adalimumab is effective and safe: Results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept
    • P.P. Van Lümig, L.L. Lecluse, R.J. Driessen, P.I. Spuls, J.B. Boezeman, and P.C. van de Kerkhof et al. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept Br J Dermatol 163 2010 838 846
    • (2010) Br J Dermatol , vol.163 , pp. 838-846
    • Van Lümig, P.P.1    Lecluse, L.L.2    Driessen, R.J.3    Spuls, P.I.4    Boezeman, J.B.5    Van De Kerkhof, P.C.6
  • 15
    • 76749092658 scopus 로고    scopus 로고
    • Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis
    • L.L. Lecluse, R.J. Driessen, P.I. Spuls, E.M. de Jong, S.O. Stapel, and M.B. van Doorn et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis Arch Dermatol 146 2010 127 132
    • (2010) Arch Dermatol , vol.146 , pp. 127-132
    • Lecluse, L.L.1    Driessen, R.J.2    Spuls, P.I.3    De Jong, E.M.4    Stapel, S.O.5    Van Doorn, M.B.6
  • 16
    • 70449725246 scopus 로고    scopus 로고
    • Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
    • T.R. Radstake, M. Svenson, A.M. Eijsbouts, F.H. van den Hoogen, C. Enevold, and P.L. van Riel et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis Ann Rheum Dis 68 2009 1739 1745
    • (2009) Ann Rheum Dis , vol.68 , pp. 1739-1745
    • Radstake, T.R.1    Svenson, M.2    Eijsbouts, A.M.3    Van Den Hoogen, F.H.4    Enevold, C.5    Van Riel, P.L.6
  • 17
    • 34447319146 scopus 로고    scopus 로고
    • Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
    • Research in Active Rheumatoid Arthritis (ReAct) Study Group
    • S. Bombardieri, A.A. Ruiz, P. Fardellone, P. Geusens, F. McKenna, K. Unnebrink Research in Active Rheumatoid Arthritis (ReAct) Study Group Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice Rheumatology 46 2007 1191 1199
    • (2007) Rheumatology , vol.46 , pp. 1191-1199
    • Bombardieri, S.1    Ruiz, A.A.2    Fardellone, P.3    Geusens, P.4    McKenna, F.5    Unnebrink, K.6
  • 18
    • 24944490986 scopus 로고    scopus 로고
    • Adalimumab in clinical practice: Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure
    • A.N. Bennett, P. Peterson, A. Zain, J. Grumley, G. Panayi, and B. Kirkham Adalimumab in clinical practice: outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure Rheumatology 44 2005 1026 1031
    • (2005) Rheumatology , vol.44 , pp. 1026-1031
    • Bennett, A.N.1    Peterson, P.2    Zain, A.3    Grumley, J.4    Panayi, G.5    Kirkham, B.6
  • 19
    • 43049162899 scopus 로고    scopus 로고
    • Treatment response to a second or third TNF-inhibitor in RA: Results from the south Swedish arthritis treatment group register
    • J.A. Karlsson, L.E. Kristensen, M.C. Kapetanovic, A. Guülfe, T. Saxne, and P. Geborek Treatment response to a second or third TNF-inhibitor in RA: results from the south Swedish arthritis treatment group register Rheumatology 47 2008 507 513
    • (2008) Rheumatology , vol.47 , pp. 507-513
    • Karlsson, J.A.1    Kristensen, L.E.2    Kapetanovic, M.C.3    Guülfe, A.4    Saxne, T.5    Geborek, P.6
  • 20
    • 77953505954 scopus 로고    scopus 로고
    • Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
    • M. Rudwaleit, F. Van den Bosch, M. Kron, S. Kary, and H. Kupper Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy Arthritis Res Ther 12 2010 R117
    • (2010) Arthritis Res Ther , vol.12 , pp. 117
    • Rudwaleit, M.1    Van Den Bosch, F.2    Kron, M.3    Kary, S.4    Kupper, H.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.